1. Home
  2. AMPH vs JANX Comparison

AMPH vs JANX Comparison

Compare AMPH & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amphastar Pharmaceuticals Inc.

AMPH

Amphastar Pharmaceuticals Inc.

HOLD

Current Price

$26.04

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Janux Therapeutics Inc.

JANX

Janux Therapeutics Inc.

HOLD

Current Price

$17.01

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMPH
JANX
Founded
1996
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.0B
IPO Year
2005
2021

Fundamental Metrics

Financial Performance
Metric
AMPH
JANX
Price
$26.04
$17.01
Analyst Decision
Hold
Strong Buy
Analyst Count
7
18
Target Price
$22.50
★ $36.24
AVG Volume (30 Days)
400.5K
★ 766.3K
Earning Date
11-05-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ 0.81
N/A
Revenue
★ $719,887,000.00
$10,000,000.00
Revenue This Year
$3.87
$194.24
Revenue Next Year
$4.90
N/A
P/E Ratio
$32.44
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$16.65
$12.12
52 Week High
$29.52
$35.34

Technical Indicators

Market Signals
Indicator
AMPH
JANX
Relative Strength Index (RSI) 56.30 47.52
Support Level $25.23 $15.83
Resistance Level $27.45 $19.16
Average True Range (ATR) 0.83 0.92
MACD -0.15 -0.05
Stochastic Oscillator 49.28 27.21

Price Performance

Historical Comparison
AMPH
JANX

About AMPH Amphastar Pharmaceuticals Inc.

Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Share on Social Networks: